BMC reiterated its Buy rating on Allos Therapeutics ALTH. At the same time, BMC left its rating unchanged at $6 after the company's new drug, Istodax, was given a PTCL approval.
On Thursday, Allos added 8.65% to its value to close the day at $2.01.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
